Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 in An Enriched Population of Treatment-Refractory Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs OPB 111077 (Primary)
- Indications Nasopharyngeal cancer; Solid tumours
- Focus Biomarker; Therapeutic Use
- 14 Jun 2017 Planned primary completion date changed from 31 May 2020 to 22 May 2020.
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.
- 20 May 2017 New trial record